Active Tuberculosis
12
0
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
1 terminated out of 12 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
New Generation IGRA in Immunocompromised Individuals
Pulmonary Aspergillosis in Tuberculosis Patients
Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA
Host Response to Infection by Direct Analysis of Leukocyte Single Cell-type Gene Expression/transcript Abundance, Direct LS-TA. a Prospective Study Will Evaluate the Performance of Direct LS-TA in Triage Febrile Patients Into Major Categories of Infections: Viral, Bacterial or Active Tuberculosis.
COMPArison of Screening Strategies for Active TuBerculosis (COMPASS-TB)
miRNA in Sweat, a Novel Digital Biomarker for Detection of Active Tuberculosis (TB)
Serological Test for the Diagnosis of TB
Performance Evaluation of the VIDAS TB-IGRA Assay.
Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
Characterization and Evaluation of Diagnostic Biomarkers for Tuberculosis
Improving the Detection of Active Tuberculosis in Accident and Emergency Departments
The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study